Sun Woo Kim is the current CEO at Deep Bio Inc. Prior to this, he was the General Manager at BLUEGA Inc. from May 2014 to January 2015. Before that, the Deputy Director at KT from October 2009 to November 2013. In this interview Sun Woo Kim discusses Deep Bio’s role within digital pathology, their commitment to building AI based medical data analysis algorithms, and the success of their flagship product, DeepDX Prostate.
Deep Bio was founded with the transformative mission: To advance patient outcomes by driving innovation in technology, while empowering clinicians by providing the tools to make critical decisions. They envision a world where clinicians are empowered with technology designed to unlock personalized insights and enhance healthcare delivery, so they can focus more on what they do best: caring for their patients.
